

IN THE SENATE

SENATE BILL NO. 1379

BY JUDICIARY AND RULES COMMITTEE

AN ACT

RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO
CODE, TO REVISE CERTAIN CONTROLLED SUBSTANCES LISTED IN SCHEDULE I.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby
amended to read as follows:

37-2705. SCHEDULE I. (a) The controlled substances listed in this sec-
tion are included in schedule I.

(b) Any of the following opiates, including their isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers and salts
is possible within the specific chemical designation:

- (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip-
eridinyl]-N-phenylacetamide);
- (2) Acetylmethadol;
- (3) Allylprodine;
- (4) Alphacetylmethadol (except levo-alphacetylmethadol also known as
levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);
- (5) Alphameprodine;
- (6) Alphamethadol;
- (7) Alpha-methylfentanyl;
- (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-pip-
eridinyl]-N-phenylpropanamide);
- (9) Benzethidine;
- (10) Betacetylmethadol;
- (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperid-
inyl]-N-phenylpropanamide);
- (12) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-
methyl-4-piperidinyl)-N-phenylpropanamide);
- (13) Betameprodine;
- (14) Betamethadol;
- (15) Betaprodine;
- (16) Clonitazene;
- (17) Dextromoramide;
- (18) Diampromide;
- (19) Diethylthiambutene;
- (20) Difenoxin;
- (21) Dimenoxadol;
- (22) Dimepheptanol;
- (23) Dimethylthiambutene;
- (24) Dioxaphetyl butyrate;
- (25) Dipipanone;

- 1 (26) Ethylmethylthiambutene;
- 2 (27) Etonitazene;
- 3 (28) Etoxeridine;
- 4 (29) Furethidine;
- 5 (30) Hydroxypethidine;
- 6 (31) Ketobemidone;
- 7 (32) Levomoramide;
- 8 (33) Levophenacymorphan;
- 9 (34) 3-Methylfentanyl;
- 10 (35) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-
- 11 eridinyl]-N-phenylpropanamide);
- 12 (36) Morpheridine;
- 13 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 14 (38) Noracymethadol;
- 15 (39) Norlevorphanol;
- 16 (40) Normethadone;
- 17 (41) Norpipanone;
- 18 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
- 19 piperidinyl] propanamide);
- 20 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 21 (44) Phenadoxone;
- 22 (45) Phenampromide;
- 23 (46) Phenomorphan;
- 24 (47) Phenoperidine;
- 25 (48) Piritramide;
- 26 (49) Proheptazine;
- 27 (50) Properidine;
- 28 (51) Propiram;
- 29 (52) Racemoramide;
- 30 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
- 31 propanamide);
- 32 (54) Tilidine;
- 33 (55) Trimeperidine.

34 (c) Any of the following opium derivatives, their salts, isomers and
35 salts of isomers, unless specifically excepted, whenever the existence of
36 these salts, isomers and salts of isomers is possible within the specific
37 chemical designation:

- 38 (1) Acetorphine;
- 39 (2) Acetyldihydrocodeine;
- 40 (3) Benzylmorphine;
- 41 (4) Codeine methylbromide;
- 42 (5) Codeine-N-Oxide;
- 43 (6) Cyprenorphine;
- 44 (7) Desomorphine;
- 45 (8) Dihydromorphine;
- 46 (9) Drotebanol;
- 47 (10) Etorphine (except hydrochloride salt);
- 48 (11) Heroin;
- 49 (12) Hydromorphanol;
- 50 (13) Methyldesorphine;

- 1 (14) Methyl dihydromorphine;
 2 (15) Morphine methylbromide;
 3 (16) Morphine methylsulfonate;
 4 (17) Morphine-N-Oxide;
 5 (18) Myrophine;
 6 (19) Nicocodeine;
 7 (20) Nicomorphine;
 8 (21) Normorphine;
 9 (22) Pholcodine;
 10 (23) Thebacon.

11 (d) Hallucinogenic substances. Any material, compound, mixture or
 12 preparation which contains any quantity of the following hallucinogenic
 13 substances, their salts, isomers and salts of isomers, unless specifically
 14 excepted, whenever the existence of these salts, isomers, and salts of iso-
 15 mers is possible within the specific chemical designation (for purposes of
 16 this paragraph only, the term "isomer" includes the optical, position and
 17 geometric isomers):

- 18 (1) ~~4-bromo-2,5-dimethoxy amphetamine;~~
 19 ~~(2) 2,5-dimethoxyamphetamine;~~
 20 ~~(3) 4-bromo-2,5-dimethoxyphenethylamine (some other names: alpha-~~
 21 ~~desmethyl-DOB, 2C-B), or any compound not specifically excepted or~~
 22 ~~listed in another schedule that can be formed from dimethoxyphenethy-~~
 23 ~~lamine by replacement of one (1) or more hydrogen atoms with another~~
 24 ~~atom(s), functional group(s) or substructure(s) including, but not~~
 25 ~~limited to, compounds such as DOB, DOC, 2C-B, 25B-NBOMe;~~
 26 ~~(4) 2,5-dimethoxy-4-ethylamphetamine (another name: DOET);~~
 27 ~~(5) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;~~
 28 ~~(6) 4-methoxyamphetamine (PMA) or any compound not specifically ex-~~
 29 ~~cepted or listed in another schedule that can be formed from methoxyam-~~
 30 ~~phetamine by replacement of one (1) or more hydrogen atoms with another~~
 31 ~~atom(s), functional group(s) or substructure(s) including, but not~~
 32 ~~limited to, compounds such as PMA and DOM;~~
 33 (73) 5-methoxy-3,4-methylenedioxy-amphetamine;
 34 (84) 5-methoxy-N,N-diisopropyltryptamine;
 35 (95) 4-methyl-2,5-dimethoxy-amphetamine (DOM, STP) Amphetamine or
 36 methamphetamine with a halogen substitution on the benzyl ring, in-
 37 cluding compounds such as fluorinated amphetamine and fluorinated
 38 methamphetamine;
 39 ~~(106) 3,4-methylenedioxy amphetamine;~~
 40 ~~(117) 3,4-methylenedioxymethamphetamine (MDMA);~~
 41 ~~(128) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-~~
 42 ~~hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-~~
 43 ~~hyl MDA, MDE, MDEA);~~
 44 ~~(139) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-~~
 45 ~~roxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-hyd-~~
 46 ~~roxy MDA);~~
 47 (140) 3,4,5-trimethoxy amphetamine;
 48 (151) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-
 49 2[2-(dimethylamino)ethyl]indole and 5-MeO-DMT);

- 1 (162) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-
2 inobutyl) indole);
3 (173) Alpha-methyltryptamine;
4 (184) Bufotenine;
5 (195) Diethyltryptamine (DET);
6 (2016) Dimethyltryptamine (DMT);
7 (217) Ibogaine;
8 (2218) Lysergic acid diethylamide;
9 (2319) Marihuana;
10 (240) Mescaline;
11 (251) Parahexyl;
12 (262) Peyote;
13 (273) N-ethyl-3-piperidyl benzilate;
14 (284) N-methyl-3-piperidyl benzilate;
15 (295) Psilocybin;
16 (3026) Psilocyn;
17 (3127) Tetrahydrocannabinols or synthetic equivalents of the sub-
18 stances contained in the plant, or in the resinous extractives of
19 Cannabis, sp. and/or synthetic substances, derivatives, and their iso-
20 mers with similar chemical structure such as the following:
- 21 i. Tetrahydrocannabinols:
 - 22 a. Δ^1 cis or trans tetrahydrocannabinol, and their opti-
23 cal isomers, excluding dronabinol in sesame oil and encapsu-
24 lated in a soft gelatin capsule in a drug product approved by
25 the U.S. Food and Drug Administration.
 - 26 b. Δ^6 cis or trans tetrahydrocannabinol, and their optical
27 isomers.
 - 28 c. $\Delta^{3,4}$ cis or trans tetrahydrocannabinol, and its optical
29 isomers. (Since nomenclature of these substances is not in-
30 ternationally standardized, compounds of these structures,
31 regardless of numerical designation of atomic positions are
32 covered.)
 - 33 d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyl-
34 octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-
35 1-ol)], also known as 6aR-trans-3-(1,1-dimethylhep-
36 tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
37 dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric
38 isomers (HU211 or dexanabinol).
 - 39 ii. The following synthetic drugs:
 - 40 a. Any compound structurally derived from (1H-indole-3-
41 yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-
42 dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or
43 (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl)carbox-
44 amide by substitution at the nitrogen atoms of the indole
45 ring or carboxamide to any extent, whether or not further
46 substituted in or on the indole ring to any extent, whether
47 or not substituted to any extent in or on the cycloalkyl,
48 cycloalkenyl, aryl ring(s) (substitution in the ring may in-
49 clude, but is not limited to, heteroatoms such as nitrogen,
50 sulfur and oxygen).

1 b. Any compound structurally derived from 3-(1-naphthyl)pyrrole by substitution at the nitrogen atom of the
 2 pyrrole ring to any extent, whether or not further substituted in the pyrrole ring to any extent, whether or not
 3 substituted in the naphthyl ring to any extent, whether or not substituted in the naphthyl ring to any extent.
 4

5 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene
 6 ring to any extent, whether or not further substituted in the indene ring to any extent, whether or not substituted
 7 in the naphthyl ring to any extent.
 8

9 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the
 10 indole ring to any extent, whether or not further substituted in the indole ring to any extent, whether or not substituted
 11 in the phenyl ring to any extent.
 12

13 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the
 14 phenolic ring to any extent, whether or not substituted in the cyclohexyl ring to any extent.
 15

16 f. Any compound structurally derived from 3-(benzoyl)indole structure with substitution at the nitrogen atom of
 17 the indole ring to any extent, whether or not further substituted in the indole ring to any extent and whether or not
 18 substituted in the phenyl ring to any extent.
 19

20 g. [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrol-
 21 o[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
 22 (WIN-55,212-2).
 23

24 h. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-
 25 243).
 26

27 i. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-
 28 5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate (CP 50,5561).
 29

30 (328) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcyclohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
 31

32 (3329) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
 33

34 (340) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;
 35

36 (351) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;
 37

38 (362) Spores or mycelium capable of producing mushrooms that contain psilocybin or psilocin.
 39

40 (e) Unless specifically excepted or unless listed in another schedule,
 41 any material, compound, mixture or preparation which contains any quantity
 42 of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the
 43 existence of such salts, isomers, and salts of isomers is possible within the
 44 specific chemical designation:
 45
 46
 47
 48

- 1 (1) Gamma hydroxybutyric acid (some other names include GHB; gamma-
2 ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hydroxybutanoic acid; sod-
3 ium oxybate; sodium oxybutyrate);
- 4 (2) Flunitrazepam (also known as "R2," "Rohypnol");
- 5 (3) Mecloqualone;
- 6 (4) Methaqualone.
- 7 (f) Stimulants. Unless specifically excepted or unless listed in an-
8 other schedule, any material, compound, mixture, or preparation which con-
9 tains any quantity of the following substances having a stimulant effect on
10 the central nervous system, including its salts, isomers, and salts of iso-
11 mers:
- 12 (1) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-
13 azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine);
- 14 (2) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-
15 ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);
- 16 (3) Substituted cathinones. Any compound, except bupropion or com-
17 pounds listed under a different schedule, structurally derived from
18 2-aminopropan-1-one by substitution at the 1-position with either
19 phenyl, naphthyl or thiophene ring systems, whether or not the compound
20 is further modified in any of the following ways:
- 21 i. By substitution in the ring system to any extent with alkyl,
22 alkylendioxy, alkoxy, haloalkyl, hydroxyl or halide sub-
23 stituents, whether or not further substituted in the ring system
24 by one (1) or more other univalent substituents;
- 25 ii. By substitution at the 3-position with an acyclic alkyl sub-
26 stituent;
- 27 iii. By substitution at the 2-amino nitrogen atom with alkyl,
28 dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the
29 2-amino nitrogen atom in a cyclic structure.
- 30 (4) Fenethylamine;
- 31 (5) Methcathinone (some other names: 2-(methyl-amino)-propioph-
32 enone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-
33 464, AL-422, AL-463 and UR1423);
- 34 (6) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-methyl-5-
35 phenyl-2-oxazolamine];
- 36 (7) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);
- 37 (8) N-ethylamphetamine;
- 38 (9) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-ben-
39 zeneethanamine).